- Palliative medicine
-
Knockdown of EMMPRIN (OX47) in MRMT-1 Carcinoma Cells Inhibits Tumor Growth and Decreases Cancer-Induced Bone Destruction and Pain
-
Yanke Chen, Jing Luan, Ting Jiang, Donghui Cai, Chao Sun, Xiaofei Wang, Xiaoge Zhao, Xingchun Gou
-
Cancer Res Treat. 2021;53(2):576-583. Published online October 29, 2020
-
DOI: https://doi.org/10.4143/crt.2020.801
-
-
 Abstract
 PDF PubReader ePub
- Purpose
Bone destruction and pain caused by cancer is one of the most devastating complications of cancer patients with bone metastases, and it seriously affects the quality of patients’ life. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a cell adhesion molecule with increased expression in a variety of tumors. This study focused to clarify the specific function of EMMPRIN in bone metastasis of breast cancer.
Materials and Methods
Adenovirus with shRNA-EMMPRIN was transfected into MRMT-1 rat breast carcinoma cells, and the MRMT-1 cells with different expression levels of EMMPRIN were implanted into the bone marrow cavity of rat tibia. Next, the effect of down-regulation of EMMPRIN was evaluated as follows: bone damage was detected by X-ray radiological and tartrate-resistant acid phosphatase staining; the tumor burden was evaluated by hematoxylin and eosin staining; the test of pain-related behaviors was assessed used the bilateral paw withdrawal mechanical threshold; and the levels of secretory factors in tumor conditioned medium were determined by using enzyme-linked immunosorbent assay.
Results
We found that down-regulation of EMMPRIN in tumor cells can simultaneously reduce tumor burden, relieve cancer-induced bone destruction and pain.
Conclusion
Materials and Methods
EMMPRIN is expected to be a therapeutic target for relieving bone metastasis of breast cancer and alleviating cancerinduced bone destruction and pain. The method of targeting EMMPRIN may be a promising strategy for the treatment of cancer in the future.
-
Citations
Citations to this article as recorded by  - Matrix metalloproteinases as attractive therapeutic targets for chronic pain: A narrative review
Xin-Yi Dai, Lin Liu, Fan-He Song, Shao-Jie Gao, Jia-Yi Wu, Dan-Yang Li, Long-Qing Zhang, Dai-Qiang Liu, Ya-Qun Zhou, Wei Mei
International Journal of Biological Macromolecules.2024; 261: 129619. CrossRef - The role and pharmacological properties of P2Y12 receptor in cancer and cancer pain
Jia-ling Hu, Wen-jun Zhang
Biomedicine & Pharmacotherapy.2023; 157: 113927. CrossRef - Cav3.2 T-Type calcium channels downregulation attenuates bone cancer pain induced by inhibiting IGF-1/HIF-1α signaling pathway in the rat spinal cord
Qingying Liu, Zhongyuan Lu, Huan Ren, Lijun Fu, Yueliang Wang, Huilian Bu, Minyu Ma, Letian Ma, Chen Huang, Jian Wang, Weidong Zang, Jing Cao, Xiaochong Fan
Journal of Bone Oncology.2023; 42: 100495. CrossRef
-
5,709
View
-
115
Download
-
3
Web of Science
-
3
Crossref
|
KCA
